Clinical factors in the selection of patients for first-line immunotherapy of lung cancer
KEYNOTE-189: chemo plus pembrolizumab for NSCLC
Side effects of chemotherapy vs. immunotherapy
Andrea B. Apolo
What does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?
Curbing cancer patients’ expectations of immunotherapy